Article

Restoring aqueous flow in early glaucoma

Robert Stegmann, MD, has spent years working on a procedure to reverse glaucoma. He demonstrated the results of canaloplasty to reinstitute aqueous flow in eyes with no flow and severely high IOP values. Dr. Stegmann, professor and chairman, Medical University of South Africa, Pretoria, delivered the Stephen A. Obstbaum, MD, Honored Lecture, titled "The Time Has Come, the Walrus Said . . . to Cure Glaucoma."

Chicago-Robert Stegmann, MD, has spent years working on a procedure to reverse glaucoma. He demonstrated the results of canaloplasty to reinstitute aqueous flow in eyes with no flow and severely high IOP values. Dr. Stegmann, professor and chairman, Medical University of South Africa, Pretoria, delivered the Stephen A. Obstbaum, MD, Honored Lecture, titled “The Time Has Come, the Walrus Said . . . to Cure Glaucoma.”

Dr. Stegmann demonstrated in detail his technique that uses a canal expander to restore normal physiologic function to the entire length of Schlemm’s canal in eyes with early glaucoma. Extensive follow-up has shown that with restitution of the physiological function, normalization of the cup is realized.

In many of his cases, the IOP levels were in the 30s and following surgery normalized to from 9 to 12 mm Hg.  He showed cases in which after 15 or 21 years of follow-up, the cupping has not increased and the IOPs have remained low.

“Early intervention can turn the disease around completely,” Dr. Stegmann said. “Operate early. Determine the diagnosis. If you can visualize two collector channels, you can achieve IOPs of 9 to 12 mm Hg. If you find only one, you can achieve 18 mm Hg. The earlier you operate the better are the chances of finding two.”

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.